Vericel’s MACI Revenue Primed for Fourth Quarter Growth

Vericel's MACI orthobiologic

Vericel reported 3Q20 orthopedic revenue of USD $24.4 million, +18.2% vs. 3Q19. With 95% of its procedure backlog complete, the company’s MACI revenue exceeded expectations in the third quarter. All of Vericel’s internal metrics for MACI trended positively, with number of surgeons and number of biopsies both increasing while biopsy conversion...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

ME

Mike Evers Mike Evers is an analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0